| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3392095
Max Phase: Preclinical
Molecular Formula: C34H57N5O7
Molecular Weight: 647.86
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)CCNC(=O)[C@H](C)NC(=O)C[C@H](O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(C)C
Standard InChI: InChI=1S/C34H57N5O7/c1-20(2)16-17-35-30(42)23(7)36-27(41)19-26(40)25(18-24-14-12-11-13-15-24)37-31(43)28(21(3)4)38-32(44)29(22(5)6)39-33(45)46-34(8,9)10/h11-15,20-23,25-26,28-29,40H,16-19H2,1-10H3,(H,35,42)(H,36,41)(H,37,43)(H,38,44)(H,39,45)/t23-,25+,26-,28-,29-/m0/s1
Standard InChI Key: DTDQTTSGSTUIBM-PBTRMENHSA-N
Associated Targets(non-human)
Cathepsin D 510 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 647.86 | Molecular Weight (Monoisotopic): 647.4258 | AlogP: 2.82 | #Rotatable Bonds: 17 |
| Polar Surface Area: 174.96 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 6 |
| #RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
| CX Acidic pKa: 12.33 | CX Basic pKa: | CX LogP: 3.22 | CX LogD: 3.22 |
| Aromatic Rings: 1 | Heavy Atoms: 46 | QED Weighted: 0.15 | Np Likeness Score: -0.08 |
References
| 1. Agarwal NS, Rich DH.. (1986) Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin., 29 (12): [PMID:3783611] [10.1021/jm00162a015] |
Source
Source(1):